Page last updated: 2024-12-11
fpl 15896ar
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9794203 |
| CHEMBL ID | 467084 |
| SCHEMBL ID | 1422817 |
| MeSH ID | M0253669 |
Synonyms (31)
| Synonym |
|---|
| fpl 15896 |
| lanicemine [inn] |
| arl 15896 |
| 9tmu325rk3 , |
| 153322-05-5 |
| (+)-2-(s)-beta-aminophenethyl-pyridine |
| ar-r 15896 |
| (+)-2-((s)-beta-aminophenethyl)pyridine |
| unii-9tmu325rk3 |
| lanicemine |
| ar-r15896ar |
| CHEMBL467084 |
| azd6765 |
| azd-6765 |
| (+)-2-((s)-.beta.-aminophenethyl)pyridine |
| lanicemine [who-dd] |
| (1s)-1-phenyl-2-pyridin-2-ylethanamine |
| gtpl7681 |
| SCHEMBL1422817 |
| AKOS026744074 |
| DB11889 |
| ZB0597 |
| (s)-1-phenyl-2-(pyridin-2-yl)ethanamine |
| Q15409412 |
| (1s)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine |
| lanicemine (free base) |
| CS-0027621 |
| HY-108235 |
| lanicemine(free base) |
| DTXSID30870011 |
| EN300-152521 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The ratios of Cmax and AUC(0-∞) of lanicemine to plasma total radioactivity were 84 and 66%, respectively, indicating that lanicemine was the major circulating component with T1/2 at 16 h." | ( Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Bui, KH; Grimm, SW; Guo, J; Zhou, D, 2015) | 0.42 |
| " The aim of this study was to develop a population pharmacokinetic model describing the concentration vs time profile of intravenously administered lanicemine in healthy subjects and patients with major depressive disorder (MDD) and to use the model to evaluate the impact of demographic and clinical factors and concomitant medication on the pharmacokinetics of lanicemine." | ( Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Agbo, F; Bui, KH; Zhou, D, 2017) | 0.46 |
| " Population pharmacokinetic analysis was performed by nonlinear mixed-effects modelling." | ( Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Agbo, F; Bui, KH; Zhou, D, 2017) | 0.46 |
| "The population pharmacokinetic model developed adequately described the clinical observation of lanicemine in patients with MDD and healthy volunteers." | ( Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Agbo, F; Bui, KH; Zhou, D, 2017) | 0.46 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " These findings are consistent with the hypothesis that the inability of memantine, AZD6765 (lanicemine) and MK-0657 to reproduce the rapid and robust antidepressant effects of ketamine in the clinic result from insufficient dosing rather than a difference in mechanism of action among these NMDAR antagonists." | ( Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. Czekaj, J; Kos, T; Popik, P; Skolnick, P, 2015) | 0.42 |
| "51 μg/mL after 150 mg daily dosing to steady state." | ( Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. Agbo, F; Bui, KH; Guo, J; Zhou, D, 2015) | 0.42 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.7025 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.7025 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.4824 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.6205 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.3268 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.7025 | 6.0000 | AID1691903 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 0.5600 | 0.0012 | 0.7025 | 6.0000 | AID1691903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (63)
Molecular Functions (22)
Ceullar Components (28)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID353103 | Displacement of [3H]MK801 from NMDA receptor in rat brain neuronal membrane | 2009 | Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9 | NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. |
| AID353104 | Ratio of Ki for rat brain NMDA receptor in presence of 100 uM spermine to Ki for rat brain NMDA receptor in absence of spermine | 2009 | Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9 | NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. |
| AID1691903 | Binding affinity to NMDAR (unknown origin) | 2020 | European journal of medicinal chemistry, May-15, Volume: 194 | Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.79) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (36.84%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (63.16%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||